Kidney Transplant — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Kidney transplantation is the surgical implantation of a donor kidney — from a living or deceased donor — into a recipient with end-stage renal disease (ESRD) to restore kidney function and eliminate dependence on dialysis. The transplanted kidney is placed heterotopically — in the right or left iliac fossa of the pelvis — where it is connected to the external iliac artery and vein and the recipient's bladder, rather than in the kidney's natural anatomical position. The native kidneys are generally left in situ unless they are causing specific problems (e.g., persistent hypertension, polycystic kidney disease with pressure symptoms, or recurrent infections). A successful kidney transplant is the optimal treatment for ESRD, offering superior long-term survival, quality of life, and cost-effectiveness compared to chronic haemodialysis or peritoneal dialysis. Kidney transplantation is the most commonly performed solid organ transplant worldwide, with over 25,000 performed annually in the United States and 3,500 in the United Kingdom. The procedure requires lifelong immunosuppression to prevent rejection of the foreign donor organ. The multidisciplinary transplant team includes transplant surgeons, nephrologists, coordinators, pharmacists, dietitians, and psychologists.

Kidney transplantation is indicated for any patient with end-stage renal disease (ESRD) — defined as GFR persistently below 15 mL/min/1.73m², irreversible chronic kidney disease stage 5 — who is medically fit for surgery and immunosuppression. Common causes of ESRD leading to transplant listing include: diabetic nephropathy (the most common cause in developed countries); hypertensive nephropathy; IgA nephropathy and other primary glomerulonephritides; polycystic kidney disease (ADPKD); focal segmental glomerulosclerosis (FSGS); lupus nephritis; and chronic allograft nephropathy from a previous transplant. Pre-emptive transplantation — before starting dialysis — when GFR falls below 20 mL/min in patients with a suitable living donor is associated with superior graft and patient survival compared to transplantation after dialysis initiation. Contraindications to transplantation include: active malignancy (solid cancers in remission <2–5 years may be acceptable depending on type); active systemic infection; significant unrevascularisable coronary or peripheral arterial disease; active substance misuse; non-compliance with medical management; and severe obesity (BMI >40 at many centres, though bariatric surgery first may be considered). Comprehensive pre-transplant workup includes cardiac assessment (echocardiography, stress testing), infection screening, cancer screening, and psychosocial evaluation.

The recipient is positioned supine and a curved (Gibson) incision is made in the right (or occasionally left) iliac fossa from the iliac crest to the pubic symphysis. The external iliac artery and vein are dissected and controlled. The donor kidney is prepared on a back table in cold ischaemia solution (University of Wisconsin or Custodiol) while the recipient vessels are prepared. The donor renal artery is anastomosed end-to-side to the recipient's external iliac artery (or end-to-end to the internal iliac artery for paediatric donors) using 5-0 or 6-0 Prolene sutures. The donor renal vein is anastomosed end-to-side to the external iliac vein. Upon releasing the vascular clamps (reperfusion), the kidney should immediately appear pink and firm as blood flow is restored — sometimes with an immediate brisk urine output (especially for living donor transplants). The ureter is implanted into the recipient's bladder (ureteroneocystostomy) using a Leadbetter-Politano or Lich-Gregoir technique with a temporary ureteric stent placed to protect the anastomosis. Cold ischaemia time (from donor procurement to reperfusion) must be minimised — ideally <24 hours for deceased donors and <4 hours for living donors — as prolonged cold ischaemia independently predicts delayed graft function and graft survival. Total surgical time is 3–4 hours.

Kidney transplantation is the gold-standard treatment for ESRD, offering survival advantage over dialysis at all ages and in virtually all comorbidity profiles that allow transplantation. Living donor kidney transplant outcomes: 1-year graft survival ~98%, 5-year ~90%, 10-year ~70–80%. Deceased donor outcomes: 1-year ~95%, 5-year ~82%, 10-year ~55–65%. Patient survival at 5 years post-transplant exceeds 85%, substantially superior to the 35–40% 5-year survival on long-term haemodialysis. ESRD patients spend on average 3.5 dialysis sessions per week (typically 4 hours per session); a functioning transplant eliminates this burden, restoring near-normal lifestyle, the ability to travel freely, to eat a less restricted diet, and to work full-time. Recombinant erythropoietin injections for anaemia and phosphate binders are generally no longer required after successful transplantation. Quality-of-life scores (SF-36, KDQOL) improve significantly in virtually all domains — physical function, vitality, social functioning, and mental health — within 6–12 months of a successful transplant. Children who receive transplants achieve normal developmental milestones in growth and cognitive development that dialysis impairs.

Early post-operative complications: delayed graft function (DGF) — the need for dialysis in the first week post-transplant — occurs in 25–30% of deceased donor transplants from ischaemia-reperfusion injury; primary non-function (<5%); surgical bleeding; urological complications (ureteric leak or obstruction, 2–5%, managed with ureteric stent or surgical revision); renal artery or vein thrombosis (rare, <1%, often causing irreversible graft loss). Immunological complications: acute T-cell mediated rejection (TCMR) occurs in 10–15% of transplants within the first year despite immunosuppression, identified by rising creatinine and confirmed by biopsy; treated with high-dose methylprednisolone pulses or anti-thymocyte globulin. Antibody-mediated rejection (ABMR) is more resistant to treatment. Chronic allograft nephropathy — progressive interstitial fibrosis and tubular atrophy — is the leading cause of late graft loss at 5–10 years. Immunosuppression-related complications: opportunistic infections (CMV disease in 5–10%, BK virus nephropathy in 3–5%, Pneumocystis pneumonia — prevented by cotrimoxazole prophylaxis); post-transplant malignancy (non-melanoma skin cancer 10-fold increased risk, lymphoma 10-fold increased); drug toxicity (tacrolimus nephrotoxicity, glucose intolerance progressing to new-onset diabetes — NODAT — in 15–25%, hypertension, dyslipidaemia); and osteoporosis from corticosteroids.

The immediate post-transplant period is managed in a specialised transplant unit with hourly urine output monitoring — brisk output from a living donor kidney (1–3 litres on day 1) is an excellent early sign. IV fluids are titrated to match urine output. Blood tests (creatinine, tacrolimus levels, FBC, electrolytes) are monitored daily initially. Immunosuppression triple therapy — tacrolimus (target trough 8–12 ng/ml in the first 3 months), mycophenolate mofetil (500–1000 mg twice daily), and prednisolone (tapered from 20 mg to 5 mg over 3 months) — is initiated peri-operatively. Prophylactic valganciclovir (against CMV and HSV), cotrimoxazole (against PCP), and fluconazole (against Candida) are prescribed for 3–6 months. Hospital discharge typically occurs at 5–10 days when the patient is stable on oral medications and creatinine is stable or improving. Clinic reviews occur twice weekly for the first month, weekly for months 2–3, then monthly for the first year. Return to light work is possible at 4–8 weeks; heavy manual labour at 3–6 months. Driving resumes when comfortable on oral analgesia (usually 4–6 weeks). Contact sports risking trauma to the transplant in the iliac fossa should be permanently avoided. Lifelong immunosuppression, sun protection (high SPF sunscreen daily, dermatology review), blood pressure control, regular renal function monitoring, and annual skin cancer surveillance are essential.